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Objective. Hypoglycemia occurs in 20% to 60% of patients with diabetes mellitus. Identifying 
at-risk patients can facilitate interventions to lower risk. We sought to develop a hypoglycemia 
prediction model. 
Methods. In this retrospective cohort study, urban adults prescribed a diabetes drug between 
2004 and 2013 were identified. Demographic and clinical data were extracted from an electronic 
medical record (EMR). Laboratory tests, diagnostic codes, and natural language processing 
(NLP) identified hypoglycemia. We compared multiple logistic regression, classification and 
regression trees (CART), and Random Forest. Models were evaluated on an independent test set 
or through cross-validation. 
Results. 38,780 patients had mean age 57 years; 56% were female, 40% African-American, and 
39% uninsured. Hypoglycemia occurred in 8,128 (539 identified only by NLP). In logistic 
regression, factors positively associated with hypoglycemia included infection, non-long-acting 
insulin, dementia, and recent hypoglycemia. Negatively associated factors included long-acting 
insulin plus sulfonylurea, and age 75 or older. Models' area under curve was similar (logistic 
regression, 89%; CART, 88%; Random Forest, 90%, with 10-fold cross-validation). 
Conclusions. NLP improved identification of hypoglycemia. Non-long-acting insulin was an 
important risk factor. Decreased risk with age may reflect treatment or diminished awareness of 






Diabetes mellitus is one of the most common non-communicable diseases worldwide and a 
major cause of morbidity and mortality [1]. An estimated 422 million people had diabetes in 
2014, and diabetes is predicted to become the seventh leading cause of death in the world by the 
year 2030 [2]. The number of people with type 2 diabetes mellitus (T2DM), the most common 
form of diabetes, is increasing in every country [1]. In the United States, the incidence of 
diabetes nearly tripled between 1990 and 2010 [3], and 1.7 million new cases were diagnosed in 
adults in 2012 [4]. Among Americans 65 or more years of age, the prevalence is 26% [4]. 
Hypoglycemia (HG) is recognized as the major limiting factor in optimal glycemic management 
for patients with diabetes [5 6]. Substantial negative effects on cardiovascular safety and quality 
of life have been noted [7-12]. It also increases economic costs, which result from healthcare 
resource utilization to manage HG and its consequences, as well as from patient absenteeism and 
lost productivity [13]. Many patients with diabetes, especially those with recurring episodes of 
HG, are unaware when HG occurs, despite the risk of serious adverse events including coma and 
death. Identifying patients at especially high risk of HG may provide an opportunity to intervene 
and reduce the incidence of events. Using electronic medical records and computer-based 
algorithms to identify HG is challenging, because diagnostic codes for HG are not consistently 
used, and are subject to underreporting. Signs or symptoms of specific episodes of HG, 
especially if not severe, might be recorded only in an unstructured, narrative (text-based) format. 
In this study, based on existing literature about HG risk, we developed a multivariable HG risk 
model for use in clinical practice by physicians and other health care professionals. Our goal in 
this analysis was to compare three popular models of prediction, applying them to HG using data 
 
 
routinely collected in an electronic health record system, and decide on one for implementation 
of clinical decision support. This would be the first HG model that combines nearly all known 





This retrospective study was approved, with a waiver of informed consent, by the Indiana 
University Institutional Review Board, protocol number 1402826879. 
2.1 design 
In this retrospective cohort study, the study period was defined to be 01 January 2004 to 31 
December 2013. Eskenazi Health is an urban safety-net medical institution [14] in Indianapolis, 
Indiana, U.S.A. In 2012, Eskenazi had 1,081 physicians on staff and serviced 950,592 outpatient 
visits, including 234,637 community health center visits. The payer mix was 38% uninsured, 
32% Medicaid, 19% Medicare, 8% commercial, and 3% other. The Indiana Network for Patient 
Care is a statewide network of electronic medical data, representing 25,000 physicians, 106 
hospitals, and 110 clinics, surgery centers, and other healthcare organizations, including 
Eskenazi Health. The network includes information "from encounters covering over 90% of care 
provided at hospitals in the Indianapolis area", including abstracts, text reports, discharge 
summaries, operative notes, pathology reports, electrocardiogram readings, radiology images, 
and medication records [15 16] The study cohort consisted of patients who received outpatient 
care at Eskenazi during the study period, as identified through computer-based query of the 
network. The study targeted electronic medical data in retrospective analysis; patients were not 
contacted. Clinical data about the cohort were extracted from the Regenstrief Medical Record 
System, an electronic health record system used by Eskenazi Health [17]. 
HG events were identified among the cohort. The index date was defined as the first date of HG 
during the study period that occurred at least two years after the patient's first encounter between 
January 2002 and December 2011. For patients in this cohort who did not experience a HG event 
 
 
during the study period, the index date was a randomly selected date of an actual visit during the 
study period. The baseline period was defined as the two-year period prior to the index date. 
Eligible patients were selected from the cohort if they met the following inclusion criteria: at 
least 21 years of age at the index date, prescribed or dispensed a drug for diabetes mellitus during 
the study period, and had at least two clinical encounters on separate dates during the baseline 
period. Drugs for diabetes were acarbose, acetohexamide, alogliptin, canagliflozin, 
chlorpropamide, colesevelam, dapagliflozin, exenatide, glibenclamide, glimepiride, glipizide, 
glyburide, insulin, linagliptin, liraglutide, meglitol, metformin, nateglinide, pioglitazone, 
pramlintide, repaglinide, rosiglitazone, saxagliptin, sitagliptin, tolazamide, and voglibose. We 
did not attempt to identify a subgroup of patients with type 1 diabetes since administrative data 
are not always reliable in distinguishing types of diabetes. Baseline covariates (predictors; see 
Table 1) culled from literature review [5 6 10 18-43] were abstracted during the baseline period. 
Medical conditions were identified by diagnostic codes in medical records. Based on previous 
studies, glomerular filtration rate [34], infection [34] within 30 days, and serum calcium [42] 
were included. See the Appendix for a listing of diagnosis and procedure codes corresponding to 
conditions. 
 
Table 1. Patients’ characteristics and baseline 







Age (years)     
21-44 7644 1547 
45-64 20,080 4470 
65-74 6916 1441 
75-84 3238 559 
≥ 85 902 111 
Gender     
Female 21,841 4816 
Male 16,939 3312 
 
 
Race     
White 18,355 2991 
Black 15,510 4439 
Spanish 1031 162 
Native American 934 218 
Unknown 2950 318 
Insurance     




Uninsured 15,013 1826 
BMI (kg/m2) 35.7 (9.8) 35.1 (10.0) 
Alcohol     
No 37,919 7703 
Yes 861 425 
Autonomic failure   
No 38,743 8114 
Yes 37 14 
Cancer     
No 37,729 7587 
Yes 1051 541 
Chronic heart failure     
No 37,198 7088 
Yes 1582 1040 
Coronary artery disease     
No 36,759 6999 
Yes 2021 1129 
Dementia or falls     
No 37,527 7438 
Yes 1253 690 
Diabetic neuropathy     
No 37,366 7291 
Yes 1414 837 
Last hospital discharge     
1-30 days before index 
date 
35,092 6133 
31-365 days 2858 1470 
> 365 days 830 525 
Infection within 30 days     
No 37,395 7284 
Yes 1385 844 
Last HbA1c     
≤ 6.5% 5321 2354 
> 6.5%, < 7% 1840 793 
≥ 7%, < 8% 3155 1369 
≥ 8%, < 9% 1773 793 
≥ 9% 3977 1789 
Missing 22,714 1030 
Serum calcium (mg/dL) 9.4 (0.7) 9.2 (0.8) 
 
 
Hypoglycemia within 12 
months 
    
No 38,121 7632 





Antibiotics within 30 
days, SU within 90 days 
    
Antibiotics and SU 765 163 
Antibiotics without SU 2602 366 
No antibiotics 35,413 7599 
Insulin and SU within 12 
months 
    
LAI without SU 4720 726 
LAI and SU, not within 
90 days 
66 11 
LAI and SU within 90 
days 
1248 144 
Non-LAI insulin without 
SU 
3055 1260 
Non-LAI insulin and 
SU, not within 90 days 
47 20 
Non-LAI insulin and SU 
within 90 days 
615 264 
SU without insulin 8727 2079 
No insulin, no SU 20,302 3624 
LAI = long-acting insulin, SU = sulfonylurea 
Note: a two-year baseline window prior to the index 
date is used for most risk factors; a one-year window for 
prior episodes of hypoglycemia was used, and a 30-day 
window for infections and antibiotic use. 
 
2.2 HG definition 
HG was defined by any of the following criteria. 
• Plasma or point-of-care glucose value of at least 5 mg/dL, and less than 70 mg/dL, 
documented in the medical record. A minimum, positive glucose value was included to 
avoid spurious values of zero. 




• ICD code 250.8 without any of the following codes [44]: 259.8, 272.7, 681.xx, 682.x, 
686.9, 707.1x, 707.2x, 707.8, 707.9, 709.3, 730.0x, 730.1x, 730.2x, 731.8. 
• Text note indicating HG, including a glucose value. 
To use NLP to evaluate text notes, we used a combination of Unstructured Information 
Management Architecture [45], a sentence tokenizer from the Open NLP project [46], and a 
regular expression system. This identified clinical reports mentioning a "blood sugar word" 
followed within five words by what could be a low blood-sugar value represented by a number in 
the range 10 to 69. We filtered (dropped) text representing dates and times, units of weight, 
strings with leading "if", and strings referencing proteins, in case protein numbers were 
documented instead of glucose values. The regular expression for a "blood sugar word" was 
"(?i)(^|\\b)(glucose|glu(?!cotrol)|gluc(?!otrol)|sugars|sugar|bs|bg|accucheck|accuchek|glucometer)
.*(,|\\.|;|$)". 
2.3 predictive modeling approaches 
We considered three predictive modeling approaches: conventional multiple logistic regression 
(LR), classification and regression trees (CART) [47], and Random Forest (RF) [48]. 
Logistic Regression 
In LR, the presence or absence of HG (dependent variable) was modelled with all baseline 
covariates in the model as main effects (independent variables). Missing values of continuous 
variables were handled by imputing the mean of observed data. Missing values of categorical 
variables except demographics were set to zero/unknown or without having the condition. 
Forward stepwise variable selection was used for including predictors in the model, using an 
entry criterion of alpha at 0.10 and a stay criterion of alpha at 0.05. Since the goal was prediction 
rather than explanation of the HG mechanism, we used a data-driven approach and did not force 
 
 
specific variables into the model. LR is commonly used in medical research. It requires the 
assumption that the relationship between the outcome and the predicting covariates is linear. 
Classification and Regression Trees 
Tree-based methods offer many appealing advantages over LR, a parametric modeling approach. 
They require no specification of the relationship of the covariates with the outcome, and 
approximate the relationship adaptively, driven by data. Trees can capture complex interactions 
among covariates, and can handle highly correlated covariates. The rank-based nature of binary 
splits in covariates also makes trees robust to outliers and invariant to monotonic transformations 
of the covariates. For example, the same predictions can be obtained whether age, log(age), or 
age2 is used. Trees also handle irrelevant covariates well; if a covariate does not predict the 
response, a tree will not include it. 
From the practical perspective, a single tree enables a visual inspection of the risk of an outcome 
based on patients’ characteristics and baseline variables, such as medication use, diagnoses, and 
laboratory results. Hence, it provides clinical interpretability and, if parsimonious, may be ideal 
for a clinical decision support tool. Trees, however, require large sample sizes for stability. The 
‘right-sized tree’ was selected by ten-fold cross-validation. 
Random Forests 
The method of Random Forests generates an ensemble of trees. Tree-based ensembles combine 
the predictions of many different trees to give an aggregated prediction, a procedure of model 
averaging. The advantage of a tree ensemble over a single tree is that it maintains the low bias of 
a single tree but with a much lower variance, achieved through averaging. For classification 
trees, using such an average amounts to using the most frequently predicted class, known as the 
‘majority vote’. Ensembles can give improved prediction accuracy over individual trees. An 
 
 
intuitive idea behind the improved accuracy of ensemble classifiers is that if the individual 
classifiers tend to make prediction errors in different regions of predictor space, then the 
incorrect predictions may be overwhelmed by the correct ones. 
One disadvantage of tree ensembles compared to a single tree is that ensembles can be difficult 
to interpret, because the average of trees is not a tree. Due to the intended use of our model in 
clinical practice, we placed significant value on accuracy of prediction. 
Evaluation of the Three Approaches 
The data set was randomly split into a training data set and a test data set in the ratio of 2:1. All 
three modeling approaches were applied to the training data set and tested on the test data set. 
Each model was fitted on the training set, and then was applied to the test set to predict HG 
events. The area under the receiver operating characteristic (ROC) curve, i.e., AUC or c-statistic, 
is a measure of the overall performance of a model, regardless of cutoffs. We calculated the 
AUC on the test set. We also estimated AUC through ten-fold cross-validation using the entire 
data set for the three approaches, as a consistency assurance in model selection. 
2.4 analysis 
Baseline covariates were summarized using percentages if categorical, or means with standard 
deviations if continuous. Multiple LR modeling was performed using SAS, version 9.4 (SAS 






The cohort had 38,780 patients with the following characteristics: mean age of 57 years, 56% 
female, 47% white, 40% African-American, 19% with Medicaid, and 39% uninsured (see Table 
1). HG was identified in 8,128 (21%) of them; a glucose value of less than 54 mg/dL was found 
in ________. Of the 8,128 with HG, NLP identified HG in 3,751, with 539 identified only by 
NLP. The median, mean, and standard deviation for number of outpatient visits in the previous 
year were 8, 10, and 9, respectively. 
 
Table 2. Logistic regression of hypoglycemia 





interval of OR 
Age (years)   
21-44 1.4 (1.3, 1.5) 
45-64 Ref.  
65-74 0.9 (0.9, 1.0) 
75-84 0.8 (0.7, 0.9) 
≥ 85 0.6 (0.5, 0.8) 
Gender   
Female 1.1 (1.0, 1.2) 
Male Ref.  
Race   
White Ref.  
Black 1.8 (1.7, 2.0) 
Spanish 0.7 (0.5, 0.8) 
Native American 0.9 (0.8, 1.1) 
Unknown 0.8 (0.7, 0.9) 
Insurance   




Uninsured 1.0 (0.9, 1.1) 
BMI (kg/m2) 1.0 (1.0, 1.0) 
Alcohol   
No Ref.  
Yes 1.6 (1.4, 1.9) 
Autonomic failure   
No 4.1 (1.8, 9.4) 
Yes Ref.  
Cancer   
 
 
No Ref.  
Yes 1.4 (1.2, 1.6) 
Chronic heart failure   
No Ref.  
Yes 1.3 (1.1, 1.5) 
Coronary artery disease   
No Ref.  
Yes 1.2 (1.1, 1.4) 
Dementia or falls   
No Ref.  
Yes 1.5 (1.3, 1.7) 
Diabetic neuropathy     
No Ref.  
Yes 1.6 (1.4, 1.8) 
Last hospital discharge   
1-30 days before index 
date 
Ref.  
31-365 days 1.1 (1.0, 1.2) 
> 365 days 1.8 (1.5, 2.1) 
Infection within 30 days   
No Ref.  
Yes 2.5 (2.2, 2.8) 
Last HbA1c   
≤ 6.5% 1.1 (1.0, 1.2) 
> 6.5%, < 7% Ref.  
≥ 7%, < 8% 1.0 (0.9, 1.1) 
≥ 8%, < 9% 1.0 (0.9, 1.2) 
≥ 9% 1.1 (0.9, 1.2) 
Missing 0.3 (0.2, 0.3) 
Serum calcium (mg/dL) 0.5 (0.5, 0.5) 
Hypoglycemia within 12 
months 
  
No Ref.  




1.0 (1.0, 1.0) 
Antibiotics within 30 
days, SU within 90 days 
  
Antibiotics and SU 1.1 (0.8, 1.4) 
Antibiotics without SU Ref.  
No antibiotics 1.2 (1.1, 1.4) 
Insulin and SU within 12 
months 
  
LAI without SU 1.1 (0.9, 1.2) 
LAI and SU, not within 
90 days 
1.5 (0.7, 3.2) 
LAI and SU within 90 
days 
0.7 (0.6, 0.9) 
Non-LAI insulin without 
SU 
2.2 (2.0, 2.5) 
 
 
Non-LAI insulin and 
SU, not within 90 days 
1.3 (0.6, 2.7) 
Non-LAI insulin and SU 
within 90 days 
1.8 (1.5, 2.2) 
SU without insulin 1.0 (1.0, 1.1) 
No insulin, no SU Ref.  
LAI = long-acting insulin, SU = sulfonylurea 
Note: logistic regression was run on the entire cohort with 
missing data imputed by mean of observed data. 
 
In LR, factors positively associated with HG included the following (Table 2): infection within 
30 days prior to event (OR 2.5; 95% CI 2.2, 2.8), insulin other than long-acting insulin (without 
SU drug, 2.2; 2.0, 2.5; with SU within 90 days, 1.8; 1.5, 2.2; vs. non-insulin and non-SU), 
previous hypoglycemia within 12 months (2.4; 1.9, 2.9), African-American (1.8; 1.7, 2.0; vs. 
white), diabetic neuropathy (1.6; 1.4, 1.8), Medicaid (1.5; 1.4, 1.6), alcohol consumption (1.6; 
1.4, 1.9), chronic heart failure (1.3; 1.1, 1.5), no antibiotics within 30 days (1.2; 1.1, 1.4), age 21 
to 44 (1.4; 1.3, 1.5; vs. age 45 to 64), and dementia or falls (1.5; 1.3, 1.7). Factors negatively 
associated with HG included serum calcium mg/dL (OR 0.5; 95% CI 0.5, 0.5), age 85 years or 
more (0.6; 0.5, 0.8; vs. age 45 to 64), long-acting insulin plus an SU within 90 days (0.7; 0.6, 
0.9), Hispanic (0.7; 0.5, 0.8), and age 75 to 84 years (0.8; 0.7, 0.9). The addition of NLP changed 
the statistical significance of coronary artery disease in the LR: the confidence interval was 1.0 to 
1.3 without NLP, and 1.1 to 1.4 with NLP. 
Performance was similar across the three models: using the ten-fold cross validation, Random 
Forest has a mean AUC 90%, LR has a mean AUC 89%, and CART a mean AUC 88%. The 
AUCs of the three models when applied to the held-out independent test set, in the 2:1 random 
split of training and test sets, are 90%, 89% and 87%, almost identical to the above from the ten-







We developed a new predictive model of HG risk among outpatients with diabetes, comparing 
three statistical methods. We observed that LR, CART, and Random Forest have similar 
performance in our data set. The lack of advantage of tree-based methods such as CART and 
Random Forest over LR could be due to the following: all of our covariates are binary or 
categorical, except glomerular filtration rate, body mass index, and serum calcium; or possible 
lack of interaction between covariates. Adaptive modeling of non-linear relationships between 
continuous predictors and an outcome, and adaptive modeling of the interactions among 
predictors, are the two primary advantages of tree-based methods in comparison with 
conventional LR and, in general, all parametric regressions. If the linearity assumption is met 
and there are no interactions between covariates, tree-based methods are at a disadvantage 
compared to LR because they afford flexibility at the price of efficiency (i.e., having higher 
variance), especially when flexibility may not be needed. 
From the standpoint of clinical care, the implications of this study are important. In developing a 
HG predictive risk model for clinical decision support, a complex predictive model does not 
need to be built for electronic health record data where most variables are binary or categorical. 
Instead, a conventional multiple LR model can be successfully employed. The LR model is 
commonly used in medical research and its coefficients are interpretable as odds ratios when 
exponentiated—a useful feature for clinicians and patients who seek to understand the relevance 
and magnitude of each factor. Furthermore, a LR model has the additional benefit of being 
straightforward to program into a risk calculator, without needing specialized software. 
 
 
Despite the advancement in pharmaceutical therapy, HG remains one of the biggest complicating 
factors in diabetes management. Although previous work over decades has identified many risk 
factors for HG, this is the first model that combines nearly all known risk factors among U.S. 
outpatients in a primary-care setting, which may afford opportunities to change long-term 
practice and introduce educational or self-management strategies for patients, to lower the risk of 
HG. Several other studies that identified risk factors for HG have not used statistical models 
[49], or focused primarily on subgroups of patients with diabetes, such patients with Medicaid 
[50], hospitalization [34 38], additional cardiovascular risk factors [51], self-reported HG [35], 
severe HG [40], symptomatic HG [25], and use of only injectable drugs for diabetes [20]. One of 
our own previous studies examined the association between HG, inpatient death, and inpatient 
length of stay among patients treated with insulin [52]. Our present study is designed to use 
electronic health record data in a way that targets all adults with diabetes and HG—except 
perhaps the mildest cases of HG, when glucose levels might not have been measured—because 
electronic health record systems create the capacity for decision support, and intervention is 
warranted in all instances of HG in any patient with diabetes, regardless of type, severity, and 
symptoms. 
NLP usefully complemented diagnostic codes and laboratory data in identifying HG, uniquely 
identifying 6.6% (539/8128) of cases of HG. Although the percentage is modest, each case of 
prevented HG can improve quality of life, morbidity, and costs. Our study did not examine 
multiplicity of HG events per patient, but this, too, would be important. The importance of NLP 
in this outpatient context is not surprising, because many cases of HG occur when patients are at 
home or otherwise away from the medical institution, without a laboratory test to confirm the 
condition. We are aware of no previous work that incorporates NLP into a statistical model of 
 
 
HG. We did not have direct access to glucometer data in this study, but some glucometers have 
capabilities to transfer their stored data electronically, paving the way for improved 
communication with healthcare providers, and control of diabetes. 
Our study confirmed many risk factors for HG while elucidating more detail about their 
magnitude in a multivariate model. Insulin other than long-acting insulin was an important risk 
factor without a sulfonylurea drug, or with a sulfonylurea drug within 90 days. Although some 
newer oral drugs for diabetes lead to HG less frequently, therapeutic inertia and other factors 
have led to a slow transition to newer drugs for many patients. In light of newer and possibly 
safer drugs, weighing the potential benefits and harms of sulfonylurea drugs is increasingly 
important. 
We were surprised to find that the oldest ages (age ≥ 75 years) were at a decreased risk for HG 
events, though Duran-Nah et al. reported this, too [25]. The finding may reflect diminished 
awareness of HG, greater attention to medical management (i.e., less aggressive management as 
a result of attention to clinical guidelines for older patients), or other unmeasured factors in this 
population. 
Since we targeted patients in a safety-net institution, the results might not be generalizable to 
other populations. We used diagnostic (ICD) codes to identify many of the covariate conditions, 
but these codes have imperfect sensitivity and specificity. Nonetheless, their usage reflects real-
world application that may transfer to other settings. We would not have captured the mildest 
cases of HG, since they might not be documented anywhere in the medical record. In this study, 
any HG, rather than severity of HG, was the outcome of interest due to the need for clinical 
 
 
intervention for HG. We did not examine C-peptide levels, duration of diabetes, use of home or 
continuous glucometry, or frequency of glucose measurement, any of which may be associated 
with outcomes. 
In summary, starting from a large set of known HG risk factors, we created a predictive risk 
model for HG using conventional LR and found that more complex models did not improve 
prediction appreciably. Given its frequent use in the medical field and its interpretability, LR is a 
feasible and potentially useful method for developing a clinical decision support tool for 
identifying HG risk in patients with type 2 diabetes. Clinicians could use these findings to 
identify and address important modifiable risk factors. Such a tool could be used by electronic 
health record systems, to automate the retrieval and presentation of risk factors for clinicians 
during medical encounters with patients with diabetes. This may lead to immediate counseling of 
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APPENDIX: DIAGNOSIS AND PROCEDURE CODES 
 
Condition ICD code except where noted 
Adrenal insufficiency 255.4, 255.5 
Alcohol 303.xx, 305.0x, 291.4, 980.0 
Autonomic failure 337.x 
Bariatric surgery CPT-4: 43770, 43644, 43645, 43842, 43843, 43844, 
43845, 43846, 43847, 43659, 43770, 43771, 43772, 
43773, 43774, 43775, 43848, 43850, 43855, 43860, 
43865, 43886, 43887, 43888, S2082, S2085 
278.01 plus any of the following CPT-4: 43.89, 44.31, 
44.38, 44.39; ICD V45.86 
Cancer 140.x-208.x 
Chronic heart failure 428.x, 402.01, 402.11, 402.91, 429.4, 398.91 
Chronic liver disease and cirrhosis 571.x 
Insulin pump V45.85 
HCPCS E0784, A9274 
Dementia or falls 331.0, 290.0, 290.1x, 290.2x, 290.3, 290.4x, 291.2, 
294.1 
E880.x, E881.x, E882, E883.x, E884.x, E885, E886.9, 
E887, E888, V15.88; 781.2, 781.3 
Depression 311, 300.4, 296.2, 296.3, 296.5, 296.6, 296.82, 296.89, 
298.0 
Diabetic neuropathy 250.6 
Eating disorder 307.1, 307.51, 307.53, 307.54 
Hypertension 401.x, 402.xx, 403.xx, 404.xx, 405.xx 
Hypothyroidism 243, 244.x 
Infection 001.x-139.x, 462,480.x-487.x, 595.x, 590.xx, 681.xx, 
682.x, 607.2, 607.81, 607.1, 616.1 
Ischemic heart disease 410.xx, 411.xx, 412, 413.x, 414.xx 
Malnutrition 263.x, 260, 261, 262 
Panhypopituitarism 253.2 
Renal failure 584.x, 585, 586, 588.x 
Stroke and cerebrovascular disease 430-438.x 
 
 
